Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Corvus Pharmaceuticals Inc
CRVS | US
15.89
USD0.10
0.60%
CRVS | US
About Corvus Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
15.89
Open
16.05
High
16.48
Low
15.58
Corvus Pharmaceuticals Inc. a clinical stage biopharmaceutical company focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006) an anti-CD73 monoclonal antibody which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818 a covalent inhibitor of ITK which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444) an oral small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182 an antibody designed to block inflammation and myeloid suppression; and CPI-935 an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals Inc. was incorporated in 2014 and is based in Burlingame California.
View LessCRVS | US
Risk
57.6
Sharpe
1.41
Luna's Score
55/100
Recommendation
Hold
Luna says (CRVS | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
60.4%1 month
57.6%3 months
343.4%6 months
244.3%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
8.80
Debt to equity
0.01
Debt to assets
0.01
Ent. to EBITDA
0.36
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-23.27M
MarketCap
993.94M
MarketCap(USD)
993.94M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-44.91
Short ratio
4.15
Short perc.
4.26
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
3.35
Range1M
6.19
Range3M
20.56
Volumes: Market Activity
Rel. volume
1.04
Price X volume
20.34M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.36 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 8.80 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 343.38 | - | Riskier |
| Debt to Equity | 0.01 | -1.23 | Expensive |
| Debt to Assets | 0.01 | 0.25 | Cheaper |
| Market Cap | 993.94M | - | Emerging |
